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CASE STUDY
Use of botulinum toxin injections 
to treat peripheral stimulator induced facial 
muscle twitching: a case report
Terrence L. Trentman1*, Jillian A. Maloney2, Christopher S. Wie1, Alanna M. Rebecca3 and David M. Rosenfeld1
Abstract 
Background: Facial pain can be a management challenge. Peripheral nerve/field stimulation may be an effective 
option for refractory cases, but direct muscle stimulation with facial twitching may result. Botulinum toxin injections 
have been used for blepharospasm and may be effective when facial stimulation results in unacceptable facial muscle 
twitching due to peripheral stimulation.
Case presentation: A 53-year old female suffered with chronic, refractory facial pain and migraines. Her facial pain 
began after a root canal of a left upper molar. She was trialed and then permanently implanted with a 1 × 8 sub-
compact percutaneous stimulator lead, resulting in improved pain control and reduced medication use. However, she 
experienced blepharospasm whenever the amplitude was above 2.75 A. Therefore, she was treated with botulinum 
toxin injections into her bilateral cheek, face, temple and occiput. This treatment provided excellent relief of the facial 
spasms, allowing her to use her stimulator at high amplitudes, and thereby maximizing her pain relief. She received 
two subsequent treatments of botulinum toxin injections at 5-month intervals with similar results.
Conclusion: Peripheral nerve/field stimulation is being used for headaches and facial pain. An undesirable side 
effect of this emerging therapy is direct muscle stimulation. Botulinum toxin injections may be an effective treatment 
modality when stimulation techniques provide pain relief but also causes muscle twitching.
© 2015 Trentman et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Peripheral nerve or field stimulation is used for a variety 
of chronic pain conditions, including headache and facial 
pain (Dodick et  al. 2015; Sweet et  al. 2015; Slavin et  al. 
2006; Yakovlev and Resch 2010). A number of complica-
tions and side effects have been reported after peripheral 
nerve and field stimulation of the head and face, includ-
ing painful stimulation, lead erosion, lead migration, and 
direct muscle stimulation (Schwedt et  al. 2007; Sharan 
et al. 2015; Trentman et al. 2008; Zach et al. 2014).
Inserting effective peripheral leads in the occipital, 
supraorbital or infraorbital regions, while simultaneously 
avoiding uncomfortable direct muscle stimulation, can be 
challenging. These areas have dense musculature which is 
needed for head movement and facial expression. Mini-
mal subcutaneous fat can complicate the challenge of 
inserting leads in an anatomic plane that provides clinical 
benefit without muscle twitching. Although intraopera-
tive checks are typically carried out in an effort to ensure 
no muscle response to peripheral stimulation, occasion-
ally patients do experience muscle twitching after occipi-
tal or facial stimulator placement, particularly when 
higher stimulation amplitudes are used.
This case report describes successful use of botuli-
num toxin injections to treat infraorbital twitching of the 
orbicularis oculi and zygomaticus major muscles after 
a permanent peripheral stimulator lead was placed for 
chronic facial pain. The use of botulinum toxin in this 
context may offer relief for patients when reprogramming 
of stimulation parameters is ineffective and the patient 
desires continued use of the device.
Open Access
*Correspondence:  trentman.terrence@mayo.edu 
1 Department of Anesthesiology and Pain Medicine, Mayo Clinic Arizona, 
5777 E Mayo Blvd, Phoenix, AZ 85054, USA
Full list of author information is available at the end of the article
Page 2 of 4Trentman et al. SpringerPlus  (2015) 4:671 
Case presentation
A 53-year-old female with a past medical history of 
chronic odontalgia and facial pain was seen in consulta-
tion for consideration of a facial stimulator trial. She also 
suffered chronic migraine headaches. Her facial pain 
began approximately 8 years earlier after a root canal of 
an upper left molar which was reportedly complicated by 
retention of a metal fragment, trigeminal nerve damage 
(V2 distribution) and chronic left facial pain. She suffered 
incapacitating pain refractory to treatment with pregaba-
lin, tramadol, tricyclic antidepressants, clonazepam, car-
bamazepine, topical lidocaine, methadone, transmucosal 
fentanyl, sphenopalatine ganglion blocks, transcutane-
ous electrical nerve stimulation (TENS), acupuncture, 
psychological approaches to pain, facial muscle steroid 
injections and radiofrequency ablation of the trigeminal 
ganglion.
After a successful percutaneous trial of facial stimula-
tion the patient was taken to the operating room for per-
manent implant. After induction of general anesthesia, 
a 14-gauge Tuohy needle was inserted subcutaneously 
through an incision on the left cheek. Under fluoro-
scopic guidance, a 1  ×  8 sub-compact percutaneous 
lead (Medtronic, Minneapolis, MN, USA) was inserted 
over the left maxilla, with care to place the distal 2 con-
tact points next to the upper molars. Several adjustments 
to the lead were necessary before a position was found 
where no muscle twitching was observed upon testing, 
even at high amplitude and low frequency stimulation 
(e.g. 10 A, 2 Hz), see Fig. 1.
Next, the lead was tunneled from the cheek to a tem-
poral incision, where it was looped and then tunneled via 
a posterior auricular route to an implantable pulse gen-
erator (IPG, RestoreUltra, Medtronic, Minneapolis, MN, 
USA) in the infraclavicular region. Because of concerns 
over erosion of bulky commercial anchors, 2-0 silk suture 
was used to anchor the lead.
On follow-up the patient noted improved pain con-
trol and reduced pain medication consumption with her 
facial stimulator; however, when she increased the ampli-
tude above 2.75, she experienced blepharospasm. After 
reprogramming failed to remedy this issue she was sub-
sequently treated with freshly prepared botulinum toxin, 
100 units/4 ml. This was injected into her bilateral cheeks 
and face, temple and occiput. The facial injections were 
based on observed muscle stimulation when the patient 
adjusted the amplitude of the device. Each facial injection 
was 0.05 ml which is 1.25 units of botulinum toxin. The 
temple and occipital regions were treated because of the 
patient’s history of migraine headaches.
This treatment provided excellent relief of the facial 
spasms, allowing her to use her stimulator at high ampli-
tudes, thereby maximizing her pain relief. She received 
two subsequent treatments of botulinum toxin injec-
tions at 5-month intervals with similar results. Her facial 
twitching began to return after about 3 months, but she 
chose to wait 2 additional months before returning to 
clinic.
Unfortunately, the following year the patient devel-
oped an infection near the post-auricular lead, and she 
had previous unrelated methicillin resistant staff aureus 
(MRSA) infections on the contralateral face. Due to 
the risk of recurrent MRSA infection combined with 
a planned instrumented spinal fusion for severe adult 
onset scoliosis, a decision was made to explant the sys-
tem to reduce the risk of seeding her spinal hardware. 
After explantation of her stimulator system, her facial 
pain returned to baseline. She has been maintained on 
oral opiates and at last follow-up, she was inquiring about 
any other pain management options.
Discussion
This case illustrates a unique potential therapy for direct 
muscle stimulation associated with a peripheral stimula-
tor: intermittent botulinum toxin injections. Although 
a number of studies discuss botulinum injections for 
hemifacial spasm, eyelid spasm, Meige Syndrome (oral 
facial dystonia) and blepharospasm (Ababneh et al. 2014; 
Czyz et al. 2013), we are unaware of reports of success-
ful treatment of stimulator related muscle contraction. In 
the present case, the botulinum toxin allowed efficacious 
stimulation until the device was removed as a risk reduc-
tion measure for other comorbidities.
Fig. 1 Lateral skull film demonstrating the location of the peripheral 
stimulation lead in relation to the left upper molars
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Botulinum toxin is produced by Clostridium botulinum 
and there are several commercially available formula-
tions of the toxin for medical use, e.g. Onabotulinumtox-
inA and RimabotulinumtoxinB. The toxin prevents the 
release of acetylcholine at the neuromuscular junction 
and thereby inhibits muscular contraction. The Food 
and Drug Administration (FDA) has approved its use for 
multiple conditions including the treatment of chronic 
migraine, cervical dystonia, severe primary axillary 
hyperhidrosis, glabellar rhytides (skin wrinkling), lateral 
canthal lines (crow’s feet), strabismus, blepharospasm, 
and hemifacial spasm.
Of particular interest in pain management prac-
tice is the recent and evolving use of botulinum toxin 
for chronic migraine, defined as a headache frequency 
≥15 days per month for 3 months in the absence of medi-
cation overuse. However, chronic migraine must be dis-
tinguished from medication overuse headache (Negro 
et al. 2011). Recent post-marketing data supports the use 
of OnabotulinumtoxinA for chronic migraine: among 254 
adults treated with OnabotulinumtoxinA, the number of 
headache and migraine days were significantly reduced, 
and the number of headache free days were increased 
(Khalil et  al. 2014). In the case presented here, the bot-
ulinum toxin may have had a synergistic pain relieving 
effect when combined with the stimulation, considering 
botulinum toxin’s pain relieving effects as seen in chronic 
migraine.
Botulinum toxin injection is not without risks and 
financial considerations. The FDA warns of the risks of 
injection of botulinum toxin including unexpected mus-
cle weakness, hoarseness, dysarthria, loss of bladder 
control, respiratory distress, dysphagia, blurred vision, 
diplopia and ptosis.
Previous studies have discussed complications of head 
and neck peripheral stimulation (Palmisani et  al. 2013). 
Lead migration is a well-known adverse event, in addition 
to complications like lead erosion, painful stimulation 
and infection. Hayek et al. discussed muscle spasms from 
occipital stimulation (Hayek et al. 2009). They described 
placing the leads higher at the nuchal line, rather than at 
the C1 level which had been previously reported (Weiner 
and Reed 1999). They found that higher lead placement 
eliminated neck muscle spasm in 5 patients.
In addition to peripheral stimulation for refractory 
headaches, a recent prospective, open-label study of 
cervical spinal cord stimulation (CSCS) in 17 chronic 
migraine subjects was carried out (Arcioni et  al. 2015). 
The authors found that paresthesia free, 10  kHz CSCS 
provided >30 % reduction in headache days for 50 % of 
the 14 patients still implanted with a permanent system 
at 6 months. Among the responders, the average reduc-
tion in headache days was 12.9.
Further studies are needed to validate neuromodu-
lation treatments for refractory headaches. An inter-
national consensus gave recommendations for further 
studies of this therapy and suggested that neurostimula-
tion devices should be reserved for refractory patients 
as part of research or only after controlled studies have 
shown the treatment to be effective (Martelletti et  al. 
2013).
Conclusion
In facial field stimulation, it may not be possible to avoid 
some degree of muscle stimulation resulting in undesir-
able twitching or spasm. In our case, every effort was 
made to identify and avoid muscle movement during 
implantation. Postoperatively, the patient suffered sig-
nificant facial muscle spasm related to stimulator use, but 
this was successfully treated with botulinum toxin. Fur-
ther studies are needed to confirm botulinum toxin as a 
reliable treatment for stimulator induced muscle spasm.
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